

# Global Life Sciences Fund I2 USD

Janus Henderson  
INVESTORS

## Fund facts at 31 March 2022

### Structure

Irish Investment Company

### Fund launch date

31 March 2000

### Fund size (USD)

4.24bn

### Index

MSCI World Health Care

### Morningstar sector

Europe OE Sector Equity Healthcare

### Fund managers

Andy Acker, CFA

### Share class launch date

31 March 2000

### NAV (USD)

57.03

### Maximum initial charge

2.00%

### Annual management charge (AMC)

1.50% pa

### Ongoing charge AMC included

1.58%

### Performance fee

N/A

### Ex-dividend date (XD)

N/A

### Pay date

N/A

### Codes

ISIN: IE0002141913

Sedol: 0214191

Bloomberg: JANGLII ID

Valor: 1060717

WKN: 935600

### Ratings

Morningstar - ★★★★★

### Objective and investment policy

The Fund aims to provide capital growth over the long term.

Performance target: To outperform the MSCI World Health Care Index by at least 2% per annum, before the deduction of charges, over any 5 year period.

The Fund invests at least 80% in shares (also known as equities) of companies, of any size, with a life sciences orientation, in any country.

The Fund is actively managed with reference to the MSCI World Health Care Index, which is broadly representative of the companies in which it may invest, as this forms the basis of the Fund's performance target. The investment manager has discretion to choose individual investments for the Fund with weightings different to the index or not in the index, but at times the Fund may hold investments similar to the index.


### Additional information

No Morningstar rating is shown if the fund is less than three years old or rating is below 3 stars. A short-term trading fee may be applied upon exiting the fund as per the prospectus. This is an Irish Investment Company regulated by the Central Bank of Ireland. Note that any differences among portfolio securities currencies, share class currencies and costs to be paid or represented in currencies other than your home currency will expose you to currency risk. Costs and returns may increase or decrease as a result of currency and exchange rate fluctuations.

### Past performance does not predict future returns.

### Cumulative Performance in (USD)

Percentage growth, 31 Mar 2012 to 31 Mar 2022.



Source: at 31 Mar 2022. © 2022 Morningstar. All rights reserved, performance is on a net of fees basis, with gross income reinvested.

■ Janus Henderson Global Life Sciences Fund I2 USD (Net) (303.9%)  
■ MSCI World Health Care NR (247.5%)  
■ Sector Equity Healthcare - OE (180.1%)

Performance %	I2 (Net)	Index	Sector	I2 (Gross)	Target (Gross)
1 month	3.5	4.8	3.0	-	-
YTD	-5.3	-3.4	-8.1	-	-
1 year	3.2	14.9	-1.1	-	-
3 years (annualised)	11.9	14.4	9.4	-	-
5 years (annualised)	12.3	12.9	9.2	14.1	15.2
10 years (annualised)	15.0	13.3	10.9	16.9	15.5

Source: at 31 Mar 2022. © 2022 Morningstar. All rights reserved, performance is with gross income reinvested. Performance/performance target related data will display only where relevant to the share class inception date and annualised target time period.

Calendar year returns %	I2 (Net)	Index	Sector
2022 to 31 Mar 2022	-5.3	-3.4	-8.1
2021	5.6	19.8	7.1
2020	24.4	13.5	20.5
2019	28.0	23.2	21.8
2018	2.8	2.5	-3.4
2017	21.5	19.8	21.7
2016	-13.2	-6.8	-9.4
2015	6.5	6.6	5.9
2014	33.7	18.1	18.3
2013	53.9	36.3	35.1
2012	23.7	17.5	18.0

Source: at 31 Mar 2022. © 2022 Morningstar. All rights reserved, performance is with gross income reinvested. Discrete performance data may change due to final dividend information being received after quarter end.

The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Source for target returns (where applicable) - Janus Henderson.

**The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.**

See next page for breakdowns and risks.

# Global Life Sciences Fund I2 USD

(continued)

**Janus Henderson**  
INVESTORS

<b>Top 10 holdings</b>	<b>(%)</b>	<b>Industry breakdown</b>	<b>(%)</b>	<b>Top 10 market capitalisation</b>	<b>(%)</b>
UnitedHealth Group Inc	5.9	Pharmaceuticals	29.8	Over \$100B	45.1
AstraZeneca PLC	4.5	Biotechnology	27.9	\$50B to \$100B	10.7
AbbVie Inc	3.9	Health Care Equipment	15.1	\$10B to \$50B	20.1
Roche Holding AG	2.9	Managed Health Care	11.4	\$5B to \$10B	10.1
Thermo Fisher Scientific Inc	2.7	Life Sciences Tools & Services	7.9	\$1B to \$5B	7.8
Abbott Laboratories	2.6	Health Care Supplies	4.3	\$500M to \$1B	1.7
Eli Lilly & Co	2.5	Health Care Services	1.5	\$250M to \$500M	1.0
Bristol-Myers Squibb Co	2.4	Health Care Distributors	1.0	\$100M to \$250M	0.3
Boston Scientific Corp	2.4	Health Care Technology	0.3	Under \$100M	0.1
Danaher Corp	2.4			N/A	2.3
<b>Total number of positions</b>	<b>143</b>				

## What are the risks specific to this fund?

- When the Fund, or a hedged share/unit class, seeks to mitigate exchange rate movements of a currency relative to the base currency, the hedging strategy itself may create a positive or negative impact to the value of the Fund due to differences in short-term interest rates between the currencies.
- The Fund could lose money if a counterparty with which the Fund trades becomes unwilling or unable to meet its obligations, or as a result of failure or delay in operational processes or the failure of a third party provider.
- Shares/Units can lose value rapidly, and typically involve higher risks than bonds or money market instruments. The value of your investment may fall as a result.
- Shares of small and mid-size companies can be more volatile than shares of larger companies, and at times it may be difficult to value or to sell shares at desired times and prices, increasing the risk of losses.
- If a Fund has a high exposure to a particular country or geographical region it carries a higher level of risk than a Fund which is more broadly diversified.
- The Fund is focused towards particular industries or investment themes and may be heavily impacted by factors such as changes in government regulation, increased price competition, technological advancements and other adverse events.
- The Fund may use derivatives towards the aim of achieving its investment objective. This can result in 'leverage', which can magnify an investment outcome and gains or losses to the Fund may be greater than the cost of the derivative. Derivatives also introduce other risks, in particular, that a derivative counterparty may not meet its contractual obligations.
- If the Fund holds assets in currencies other than the base currency of the Fund or you invest in a share/unit class of a different currency to the Fund (unless 'hedged'), the value of your investment may be impacted by changes in exchange rates.
- Securities within the Fund could become hard to value or to sell at a desired time and price, especially in extreme market conditions when asset prices may be falling, increasing the risk of investment losses.
- Some or all of the ongoing charges may be taken from capital, which may erode capital or reduce potential for capital growth.

## General risks

- Past performance does not predict future returns.
- The value of an investment and the income from it can fall as well as rise and you may not get back the amount originally invested.
- Tax assumptions and reliefs depend upon an investor's particular circumstances and may be subject to change.

For further information please visit our website at [www.janushenderson.com](http://www.janushenderson.com) Email: [sales.support@janushenderson.com](mailto:sales.support@janushenderson.com)

Tel: +44 20 7818 1818 Fax: +44 20 7818 1819 Or talk to your usual Janus Henderson Investors representative.

# Global Life Sciences Fund I2 USD

(continued)

Janus Henderson  
INVESTORS

## Important information

**The investments underlying this financial product (referred to as the Fund) do not take into account the EU criteria for environmentally sustainable economic activities. While the analysis of ESG factors is an integral component across the Investment Manager's investment capabilities, the Investment Manager does not maximise portfolio alignment with sustainability risks as a separate goal in its own right nor does it precisely attribute the impact of ESG factors on returns for the Fund. The Investment Manager does not consider the adverse impacts of investment decisions on sustainability factors as set out under SFDR with respect to the Fund because it is not classified under either Article 9 or Article 8 of Regulation (EU) 2019/2088.** Source: Janus Henderson Investors. All ongoing charges stated are as per latest published report and accounts. Fund charges will impact the value of your investment. In particular, the ongoing charges applicable to each fund will dilute investment performance, particularly over time. For further explanation of charges please visit our Fund Charges page at <http://www.janushenderson.com>. Please note: due to rounding the figures in the holdings breakdowns may not add up to 100%. Investment into the fund will acquire units/shares of the fund itself and not the underlying assets owned by the fund. For Qualified investors, institutional, wholesale client use only. Issued in: (a) Europe by Janus Capital International Limited ("JCIL"), authorised and regulated in the U.K by the Financial Conduct Authority, Janus Henderson Investors (Schweiz) AG (reg no. CHE-109.853.110 at Dreikönigstrasse 12, CH-8002 Zurich), and Henderson Management S.A. (reg no. B22848) is incorporated and registered in Luxembourg with registered office at 2 Rue de Bitbourg, L-1273 Luxembourg and authorised by the Commission de Surveillance du Secteur Financier and (b) Dubai by JCIL authorised and regulated by the Dubai Financial Services Authority as a Representative Office. JCIL acts as lead investment adviser to Janus Henderson Capital Funds plc (JHCF). Janus Henderson Investors US LLC, Janus Henderson Investors (Singapore) Limited, INTECH Investment Management LLC, Henderson Global Investors Limited, Kapstream Capital Pty Limited and Perkins Investment Management LLC will act as sub-adviser to JCIL. JHCF is a UCITS established under Irish law, with segregated liability between funds. Investors are warned that they should only make their investments based on the most recent Prospectus which contains information about fees, expenses and risks, which is available from all distributors and Paying/Facilities agents, it should be read carefully. This is a marketing communication. Please refer to the prospectus of the UCITS and to the KIID before making any final investment decisions. The Prospectus is also available from [janushenderson.com](http://janushenderson.com). Portfolio Holdings are subject to change without notice. An investment in the fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons. This document is not for use in any country or with any individuals who are not eligible to invest in this Fund. JHCF is not regulated by the Financial Conduct Authority and the protections available under the Financial Services Compensation Scheme and the Financial Ombudsman Service will not be available in connection with an investment. Past performance does not predict future returns. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements. Shares, if redeemed, may be worth more or less than their original cost. This document is provided for information purposes only and is not an invitation to purchase any JHCF Funds. Janus Henderson Group plc and its subsidiaries are not responsible for any unlawful distribution of this document to any third parties, in whole or in part, or for information reconstructed from this presentation and do not guarantee that the information supplied is accurate, complete, or timely, or make any warranties with regards to the results obtained from its use. The performance data does not take into account the commissions and costs incurred on the issue and the redemption of shares. This communication does not constitute an offer or a recommendation to sell or purchase any investment. The extract prospectus (edition for Switzerland), the articles of incorporation, the extract annual and semi-annual report, in German, can be obtained free of charge from the representative in Switzerland: First Independent Fund Services Ltd ("FIFS"), Klausstrasse 33, CH-8008 Zurich, Switzerland, tel: +41 44 206 16 40, fax: +41 44 206 16 41, web: [www.fifs.ch](http://www.fifs.ch) The Swiss paying agent is: Banque Cantonale de Genève, 17, quai de l'Île, CH-1204 Geneva. In Ireland the Facilities Agent is Citi Fund Services (Ireland) Limited. Its custodian is JP Morgan Bank (Ireland) Plc. The last share prices can be found on [www.fundinfo.com](http://www.fundinfo.com). Copies of the Fund's prospectus, Key Investor Information Document, articles of incorporation, annual and semi-annual reports are available in English and other local languages as required from [www.janushenderson.com](http://www.janushenderson.com). These documents can also be obtained free of cost from the local offices of Janus Henderson Investors: 201 Bishopsgate, London, EC2M 3AE for UK. The summary of Investors Rights is available in English from <https://www.janushenderson.com/summary-of-investors-rights-english>. Henderson Management SA may decide to terminate the marketing arrangements of this Collective Investment Scheme in accordance with the appropriate regulation. Not for onward distribution. We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes. Janus Henderson, Knowledge Shared and Knowledge Labs are trademarks of Janus Henderson Group plc or one of its subsidiaries. © Janus Henderson Group plc.